Medical Weight Loss

Semaglutide and Tizepatide Therapy are FDA-approved weight loss medication therapies.  The medications are administered once weekly via subcutaneous injection or daily sublingual drops and produce an average weight loss of up to 20% of one's original body weight.

When used for weight loss, Semaglutide and Tirzepatide slows the emptying of the stomach by binding to the receptors that are located in the lining of the stomach. The slower emptying of the stomach sends a signal of fullness to the brain. This helps reduce your food intake and decreases your appetite, two things that are necessary for weight loss, because you feel full and are less likely to want to eat.

Results will vary for every client. Healthy weight loss is 1/2-2 pounds per week. Studies have shown that patients who have used Tirzepatide and Semaglutide have lost between 15-25% of their total body weight. Again, this is patient specific, and no results are guaranteed.

Add an answer to this itemSemaglutide and Tirzepatide come in the form of a sterile liquid solution that is administered via subcutaneous injection once weekly..

Add an answer to this item.The most common side-effect of Semaglutide is nausea and possibly other digestive issues, such as constipation, vomiting, and abdominal pain. But we take proactive measures to ensure that the chances of this happening to you are slim.

For your first month, we will start you at a lower dose of Semaglutide to allow your body to get used to it. We typically increase incrementally at month two and month three, however, everyone is different. The goal is for you to lose a few pounds a week with no nausea.

Add an answer to this18 years old 

• Pregnant/breastfeeding  
• Type 1 diabetes mellitus   
• Hypersensitivity to Semaglutide or any components of this medication  
• Personal or family history of medullary thyroid carcinoma  
• History of multiple endocrine neoplasia syndrome  
• History of pancreatitis 
• End stage renal disease (on dialysis)  BMI<25  
• Type 2 diabetic patients that are on insulin or a sulfonylurea  
• Patients with diabetic retinopathy  Patients with that are on several antihypertensive medications  item.

- Nausea

- Diarrhea

- Decreased appetite

- Vomiting

- Constipation  

- Indigestion

- Stomach (abdominal) pain 

Patients with a history of pancreatitis 

Patients with type 1 diabetes mellitus 

Patients with:

- A personal or family history of medullary thyroid carcinoma (MTC) 

- A personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 

- Known serious hypersensitivity to Tirzepatide